Table 3.

Multivariate proportional hazards regression analysis of transplant outcomes in 510 patients with MDS treated with unrelated donor marrow transplantation

RR (95% CI)PFavorable
Neutrophil engraftment    
 Cell dose 1.10  (1.03-1.18) .006 Higher  
 Donor sex (female) 0.76  (0.60-0.93) .01 Male  
 Recipient sex (female) 1.24  (1.00-1.53) .05 Female  
 Year of infusion (1988-1993) 0.67  (0.48-0.94) .02 Recent transplantation 
Acute GVHD    
 Year of infusion (1988-1993) 1.91  (1.21-3.02) .0006 Recent transplantation  
 HLA-A, -B, -DRB1 match 0.65  (0.45-0.94) .02 Match  
 Preparative regimen 1.73  (1.08-2.76) .02 No TBI 
Relapse    
 RAEB-t 4.92  (1.96-12.4) .0007 RA  
 AML 7.67  (3.03-19.4) .0001 RA  
 Acute GVHD 0.52  (0.29-0.95) .03 Grades II-IV  
Treatment-related mortality    
 Acute GVHD 2.52  (1.90-3.34) .0001 Grades 0-I  
 HLA-A, -B, -DRB1 match 0.66  (0.50-0.88) .004 Match  
 Recipient CMV serology 1.46  (1.13-1.89) .004 Negative  
 Recipient age 1.13  (1.04-1.22) .005 Younger  
 Donor age 1.20  (1.04-1.39) .01 Younger  
Overall survival    
 Acute GVHD 2.13  (1.66-2.74) .0001 Grades 0-I  
 AML 2.08  (1.46-2.97) .0001 RA  
 RAEB-t 1.66  (1.18-2.35) .004 RA  
 Cell dose 0.89  (0.83-0.96) .003 Higher  
 Recipient CMV serology 1.44  (1.14-1.81) .002 Negative  
 Time to transplantation (< 9 mo) 0.76  (0.61-0.96) .02 Early transplantation  
 Year of infusion (1988-1993) 1.45  (1.02-2.06) .04 Recent transplantation  
 HLA-A, -B, -DRB1 match 0.78  (0.60-1.00) .05 Match  
Disease-free survival    
 Acute GVHD 1.93  (1.50-2.47) .0001 Grades 0-I  
 AML 2.04  (1.43-2.91) .0001 RA  
 RAEB-t 1.71  (1.22-2.40) .002 RA  
 Cell dose 0.89  (0.83-0.96) .003 Higher  
 Recipient CMV serology 1.46  (1.16-1.84) .001 Negative  
 Time to transplantation (< 9 mo) 0.78  (0.62-0.98) .03 Early transplantation  
 Year of infusion (1988-1993) 1.43  (1.01-2.01) .03 Recent transplantation 
RR (95% CI)PFavorable
Neutrophil engraftment    
 Cell dose 1.10  (1.03-1.18) .006 Higher  
 Donor sex (female) 0.76  (0.60-0.93) .01 Male  
 Recipient sex (female) 1.24  (1.00-1.53) .05 Female  
 Year of infusion (1988-1993) 0.67  (0.48-0.94) .02 Recent transplantation 
Acute GVHD    
 Year of infusion (1988-1993) 1.91  (1.21-3.02) .0006 Recent transplantation  
 HLA-A, -B, -DRB1 match 0.65  (0.45-0.94) .02 Match  
 Preparative regimen 1.73  (1.08-2.76) .02 No TBI 
Relapse    
 RAEB-t 4.92  (1.96-12.4) .0007 RA  
 AML 7.67  (3.03-19.4) .0001 RA  
 Acute GVHD 0.52  (0.29-0.95) .03 Grades II-IV  
Treatment-related mortality    
 Acute GVHD 2.52  (1.90-3.34) .0001 Grades 0-I  
 HLA-A, -B, -DRB1 match 0.66  (0.50-0.88) .004 Match  
 Recipient CMV serology 1.46  (1.13-1.89) .004 Negative  
 Recipient age 1.13  (1.04-1.22) .005 Younger  
 Donor age 1.20  (1.04-1.39) .01 Younger  
Overall survival    
 Acute GVHD 2.13  (1.66-2.74) .0001 Grades 0-I  
 AML 2.08  (1.46-2.97) .0001 RA  
 RAEB-t 1.66  (1.18-2.35) .004 RA  
 Cell dose 0.89  (0.83-0.96) .003 Higher  
 Recipient CMV serology 1.44  (1.14-1.81) .002 Negative  
 Time to transplantation (< 9 mo) 0.76  (0.61-0.96) .02 Early transplantation  
 Year of infusion (1988-1993) 1.45  (1.02-2.06) .04 Recent transplantation  
 HLA-A, -B, -DRB1 match 0.78  (0.60-1.00) .05 Match  
Disease-free survival    
 Acute GVHD 1.93  (1.50-2.47) .0001 Grades 0-I  
 AML 2.04  (1.43-2.91) .0001 RA  
 RAEB-t 1.71  (1.22-2.40) .002 RA  
 Cell dose 0.89  (0.83-0.96) .003 Higher  
 Recipient CMV serology 1.46  (1.16-1.84) .001 Negative  
 Time to transplantation (< 9 mo) 0.78  (0.62-0.98) .03 Early transplantation  
 Year of infusion (1988-1993) 1.43  (1.01-2.01) .03 Recent transplantation